Table III.
Patient outcome.
| Outcome | On TKIs (n=33) | Off TKIs (n=13) |
|---|---|---|
| Median follow-up, months (range) | 34 (1–143) | 107 (44–177) |
| Median follow-up after TKI | – | 28 (10–60) |
| discontinuation, months (range) | ||
| Disease status | ||
| First CMR | 20 | 7 |
| Second CMR | 1 | 4 |
| CHR | 11 | 2 |
| Disease progression | 1 | 0 |
| Cause of death | 4 | 0 |
| Lung cancer | 1 | |
| Pulmonary infarction | 1 | |
| Uterine cancer | 1 | |
| CML blast crisis | 1 |
TKI, tyrosine kinase inhibitor; CMR, complete molecular response; CHR, complete hematological response; CML, chronic myeloid leukemia.